logo
Plus   Neg
Share
Email

Novartis: Cosentyx Shows Long-lasting Efficacy In FUTURE 5 Trial - Quick Facts

Novartis (NVS) said new data from the FUTURE 5 trial demonstrated that 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose) of psoriatic arthritis patients treated with Cosentyx found no radiographic progression at 2 years. Clinical responses were also maintained throughout the duration of the study.

FUTURE 5 is a Phase III, randomized, double-blind, placebo-controlled study evaluating Cosentyx on radiographic progression across 2 years in PsA patients. In the study, 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A survey has shown that while a majority of Americans want to buy a car that contributes substantially to the U.S. economy amid rising trade tensions, most of the "American-made" cars are actually produced by foreign automakers. According to Cars.com's 2019 American-Made Index, the most 'American-made' vehicle in 2019 is the Jeep Cherokee. Streaming giant Netflix Inc. (NFXL) is set to lose the right to stream "The Office," one of the most popular TV show on the service. NBC Universal announced it is taking back the popular TV show for its own streaming platform, beginning January 2021. "We're sad that NBC has decided to take The... Chinese smartphone maker Xiaomi has announced that its recently launched Mi Band 4 crossed 1 million units sales in just eight days. Xiaomi's Director of Product Management Donovan Sung tweeted this news as he thanked Mi fans for the achievement. "Sharing some great news with our global Mi Fans....
Follow RTT